Compare EMN & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EMN | CORT |
|---|---|---|
| Founded | 1920 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 9.7B |
| IPO Year | 1996 | 2001 |
| Metric | EMN | CORT |
|---|---|---|
| Price | $65.77 | $117.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 5 |
| Target Price | $79.31 | ★ $96.50 |
| AVG Volume (30 Days) | ★ 958.2K | 853.1K |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.77% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.51 | 0.09 |
| Revenue | ★ $8,752,000,000.00 | $761,407,000.00 |
| Revenue This Year | $3.06 | $26.08 |
| Revenue Next Year | $3.47 | $26.98 |
| P/E Ratio | ★ $26.48 | $1,284.78 |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $56.11 | $28.66 |
| 52 Week High | $83.47 | $126.38 |
| Indicator | EMN | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 38.83 | 55.49 |
| Support Level | $65.72 | $108.33 |
| Resistance Level | $70.42 | $124.30 |
| Average True Range (ATR) | 1.27 | 5.48 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 28.72 | 73.81 |
Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.